# Sanders Morris Harris

> Sanders Morris Harris is a VC fund backing Biotechnology and Software. See 10 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Houston, United States
- Total investments: 10
- Last investment: Feb 2023
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/sandersmorrisharris/
- X (Twitter): https://twitter.com/SMH_Services
- Website: http://www.smhgroup.com
- Facebook: https://www.facebook.com/SandersMorrisHarris/

Sanders Morris Harris is a VC fund in Houston focused on Biotechnology and Software. ​Sanders Morris Harris was founded in 1987 to formulate a financial services firm that could not only capitalize on investment opportunities – but could actually create them.

## Contacts

5 contacts available for Sanders Morris Harris. Shizune tracks 1 team members at Sanders Morris Harris. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sanders-morris-harris?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 30% |
| Software | 2 | 20% |
| Pharmaceutical | 2 | 20% |
| SaaS | 1 | 10% |
| Internet | 1 | 10% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 3 | 30% |
| Series B | 2 | 20% |
| Series C | 2 | 20% |
| Series A | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 40% |
| Germany | 2 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Don Sanders | Founder | 2 | https://shizune.co/investors/profile/don-sanders |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Olatec Therapeutics | Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Parkinson's and Alzheimer’s disease, spinalcord injury, multiple sclerosis, type-2 diabetes, melanoma, pancreatic and breast cancers, among others.By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL 1B and IL 18Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands. | $40M | Series A | Feb 23, 2023 |  |
| Olatec Therapeutics | Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Parkinson's and Alzheimer’s disease, spinalcord injury, multiple sclerosis, type-2 diabetes, melanoma, pancreatic and breast cancers, among others.By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL 1B and IL 18Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands. | $40M | Series A | Feb 23, 2023 |  |
| Jerini | - Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technologydevelopment. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis. | $34M | Series B | Jun 08, 2004 |  |
| Lombardi Software | Lombardi Software, Inc. provides a suite of business process management (BPM) software and services in the United States. Its products include Teamworks 6, a BPM software suite that offers a platform to deliver applications that support process improvement; and Blueprint, a software-as-a-service-based BPM product for companies to map businessprocesses, identify problems, and prioritize improvement opportunities, as well as provides process documentation and workflow diagramming tools. The company also offers process definition and deployment solutions, on-demand assistance, and education services, as well as on-site services, including mapping, modeling analysis and optimization, process design and development, project management, and SOA integration solution reviews. Its customers include financial services, government, healthcare, insurance, life sciences, manufacturing, retail, and telecommunications industries. The company was founded in 1999 and is headquartered in Austin, Texas. | $10M |  | Mar 29, 2004 |  |
| Lombardi Software | Lombardi Software, Inc. provides a suite of business process management (BPM) software and services in the United States. Its products include Teamworks 6, a BPM software suite that offers a platform to deliver applications that support process improvement; and Blueprint, a software-as-a-service-based BPM product for companies to map businessprocesses, identify problems, and prioritize improvement opportunities, as well as provides process documentation and workflow diagramming tools. The company also offers process definition and deployment solutions, on-demand assistance, and education services, as well as on-site services, including mapping, modeling analysis and optimization, process design and development, project management, and SOA integration solution reviews. Its customers include financial services, government, healthcare, insurance, life sciences, manufacturing, retail, and telecommunications industries. The company was founded in 1999 and is headquartered in Austin, Texas. | $13M | Series C | Feb 10, 2003 |  |
| IndX Software Corporation | IndX Software is an enterprise software company that designs and markets operations intelligence solutions for Fortune 2000 businesses (i.e., primarily process manufacturing) and their supply chains. The company’s product, XHQ, provides a single, coherent view of information that users need for real-time decision support or performance management,by extracting and integrating data from multiple, disparate back-end systems, aggregating and managing content, and distributing information to users. In 1999, Marwit led a $10 million equity investment in the Company. | $7.5M |  | Jan 30, 2003 |  |
| DIREVO Industrial Biotechnology | DIREVO provides customized solutions for various industries via the development and optimization of biocatalysts with its proprietary ultra-high-throughput screening platform. Serving the Feed & Food industries and chemical / biorefinery businesses, DIREVO products are developed either independently or in conjunction with global leaderssuch as Genencor (a division of Danisco A/S), AB Enzymes, Roal Ltd. and Nestlé. DIREVO Industrial Biotechnology GmbH is privately owned and located in Cologne, Germany. The shareholders include Wölbern EquityPartner GmbH (Hamburg), NRW Bank (Düsseldorf), TVM Capital (Munich), Danisco A/S (Copenhagen), a private equity firm affiliated with Sparkasse KölnBonn (Cologne), SandersMorrisHarris EnzymesLLC (New York), Mulligan BioCapital (Hamburg), and several private investors. | $10.5M | Series B | Dec 06, 2002 |  |
| Wayport | Wayport operates WiFi hotpots for partners since 1998 with key investors Seven Rosen Funds, New Enterprise Associates, Millennium Technology Ventures and Scale Venture Partners. | $15M |  | Mar 11, 2002 |  |
| Jerini | - Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technologydevelopment. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis. | $21.9M | Series B | Nov 13, 2001 |  |
| IndX Software Corporation | IndX Software is an enterprise software company that designs and markets operations intelligence solutions for Fortune 2000 businesses (i.e., primarily process manufacturing) and their supply chains. The company’s product, XHQ, provides a single, coherent view of information that users need for real-time decision support or performance management,by extracting and integrating data from multiple, disparate back-end systems, aggregating and managing content, and distributing information to users. In 1999, Marwit led a $10 million equity investment in the Company. | $10M | Series C | Jan 19, 2000 |  |

10 of 10 investments shown.

## Co-investors
- [Milano Investment Partners SGR](https://shizune.co/investors/profile/milano-investment-partners) — VC Fund, 4 deals together
- [Techno Venture Management](https://shizune.co/investors/profile/tvm-techno-venture-management) — VC Fund, 3 deals together
- [3i Group](https://shizune.co/investors/profile/3i-group) — VC Fund, 2 deals together
- [Advection Growth Capital](https://shizune.co/investors/profile/advection-growth-capital) — VC Fund, 2 deals together
- [Austin Ventures](https://shizune.co/investors/profile/austin-ventures) — VC Fund, 2 deals together
- [Excalibur Partners](https://shizune.co/investors/profile/excalibur-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Sanders Morris Harris invest in?

Sanders Morris Harris invests primarily in Biotechnology, Software and Pharmaceutical startups, most often at Funding Round and Series B stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Sanders Morris Harris?

Public channels for Sanders Morris Harris include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sanders Morris Harris?

The team at Sanders Morris Harris includes Don Sanders (Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co